Project Grant HT94252411093
Award Date
9/15/24
Completion Date
9/14/27
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14203, USA
Similar Awards
The Defense Health Agency awarded a $168,200 Project Grant to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development program (CFDA 12.420) to investigate alternative polyadenylation as a mediator of therapeutic resistance in lung cancer. The two-year award beginning July 1, 2021 will support research into innovative medical solutions for lung cancer treatment through the study of alternative polyadenylation, a novel area of investigation that could help...
This $1,301,250 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by Health Research, Inc. to investigate methods for inhibiting myeloid-derived suppressor cell (MDSC) biogenesis to enhance the efficacy of immunotherapy in triple-negative breast cancer. The award, effective from March 1, 2025 to February 29, 2028, will fund advanced biomedical research to explore innovative approaches for transforming...
This federal Project Grant award of $872,237.00 was granted by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports a research project titled "Pulmonary Rehabilitation in Advanced Lung Cancer Survivors" to be conducted by Case Western Reserve University in Cleveland, Ohio. The project aims to investigate innovative approaches to disease prevention, diagnosis, treatment, and management of lung cancer, with a particular...
This $159,900 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports preclinical research on brain metastases in lung cancer. The award will fund studies at the University of Illinois to develop and evaluate novel drug efficacy and resistance models for advancing the treatment of brain metastases, a significant challenge in lung cancer management. Spanning one year from August 2024 to August...
Health Research, Inc. Roswell Park Division received a $559,647 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research using microfluidic lung cancer models. The two-year award, made on June 1, 2023 and set to conclude on May 31, 2025, will support investigating novel drug resistance mechanisms in lung cancer through "Microfluidic Lung Cancer On A Chip" models. As a past recipient of Defense...
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
This federal Project Grant award of $783,023.00 was issued on June 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports a precision-medicine approach to targeting acquired therapeutic resistance in RTK-mutated non-small cell lung cancer (NSCLC). The awardee, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., will conduct advanced biomedical research initiatives focused on transforming...
This federal Project Grant award, valued at $705,263.00 and effective from September 30, 2024 to September 29, 2027, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research at Northwestern University's Sponsored Research Division to conduct single-cell tracking of the transformation of lung adenocarcinoma to small cell lung cancer. This cutting-edge research aims to advance the scientific understanding of lung...
This $845,250 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by Duke University to engineer TCR-T cells to target human endogenous retroviruses for non-small cell lung cancer immunotherapy. The award period extends from July 1, 2025 to June 30, 2028. This research aims to develop innovative T-cell receptor (TCR)-based immunotherapies to treat non-small cell lung cancer by...
This federal Project Grant award of $708,000.00 provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The research project is focused on investigating the "Prevalence and Biologic Impact of FGFR3 Genomic Alterations in Bladder Cancer". The 2-year award period runs from September 15, 2023 to...